KRAS and lung cancer: Similarly, in KRAS-mutant lung cancers, PFS (5.0 months, 95% CI 3.67–6.33) was inferior compared with EGFR-mutant (6.5 months, p = 0.242) and ALK/ROS1-rearranged (9.2 months, p = 0.007) lung cancers.